IP Library Granted Patent US 7,741,476
Granted Patent B2
US 7,741,476 · App. 10/552,309 · Granted Jun 22, 2010

Cross-linking of low and high molecular weight polysaccharides preparation of injectable monophase hydrogels and polysaccharides and hydrogels thus obtained

Assignee: Allergan Industrie, SAS
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,741,476
App. No.
10/552,309
Granted
Jun 22, 2010
Kind
B2
Abstract

A process for the crosslinking of at least one polymer selected from polysaccharides and derivatives thereof, which is carried out in an aqueous solvent by the action of an effective and non-excessive amount of at least one crosslinking agent, characterized in that it is carried out on a mixture containing at least one low-molecular weight polymer and at least one high-molecular weight polymer. A process for the preparation of an injectable monophase hydrogel of at least one crosslinked polymer selected from polysaccharides and derivatives thereof is also disclosed. Crosslinked polymers and injectable monophase hydrogels, respectively, are obtainable by each of said processes.

Claims (26)

1. Process of preparing a cross-linked polymer comprising 1) forming a mixture of a first hyaluronic acid salt product having a first molecular weight and a second hyaluronic acid salt product having a second molecular weight greater than the first molecular weight, wherein the first hyaluronic acid salt product and the second hyaluronic acid salt product are two separate pre-existing products prior to the forming step; and 2) cross-linking the mixture of step 1) in an aqueous solvent in the presence of an effective and non-excessive amount of at least one cross-linking agent, such that the degree of cross-linking, defined by the ratio: 100×(total number of reactive groups in said cross-linking agent/total number of disaccharide units in the first hyaluronic acid salt and second hyaluronic acid salt), is theoretically between 0.5 and 70%.

2. Process according to claim 1 , wherein at least one of the first and second hyaluronic acid salt products is selected from a sodium salt, a potassium salt, and mixtures thereof.

3. Process according to claim 1 , wherein

the first hyaluronic acid salt product has a molecular weight of no greater than 9.9×10 5 Da; and

the second hyaluronic acid salt product has a molecular weight of at least 10 6 Da.

4. Process according to claim 1 , wherein said mixture has an intrinsic viscosity of less than 1900 ml/g.

5. Process according to claim 1 wherein said mixture contains more than 50% by weight of the first hyaluronic acid salt product and less than 50% by weight of the second hyaluronic acid salt product.

6. Process according to claim 1 , wherein said mixture contains at least 5% by weight of the second hyaluronic acid salt product.

7. Process according of claim 1 , wherein said cross-linking agent is selected from bifunctional crosslinking agents and mixtures thereof.

8. Process according to claim 1 , wherein the degree of cross-linking is theoretically between 4 and 50%.

9. Process for the preparation of an injectable monophase hydrogel of at least one cross-linked hyaluronic acid salt product comprising:

formulating the cross-linked mixture according to claim 1 , neutralized if necessary, into a solution buffered to a pH of between 6.5 and 7.5.

10. Process according to claim 1 , wherein at least one of the first and second hyaluronic acid salt products is a sodium salt.

11. Process according to claim 1 , wherein the mixture contains about 90% by weight of the first hyaluronic acid salt product and about 10% by weight of the second hyaluronic acid salt product, the first hyaluronic acid salt product is a sodium salt having a molecular weight of about 3·10 5 Da, and the second hyaluronic acid salt product is a sodium salt having a molecular weight of about 3·10 6 Da.

12. Process according to claim 1 , wherein the first hyaluronic acid salt product has a molecular weight of between 10 4 Da and 9.9×10 5 Da, and the second hyaluronic acid salt product has a molecular weight of between 10 6 Da and 10 8 Da.

13. Process according to claim 1 , wherein the second hyaluronic acid salt product has a molecular weight of between 1.1×10 6 Da and 5×10 6 Da.

14. Process according to claim 1 , wherein said mixture contains more than 70% by weight the first hyaluronic acid salt product and less than 30% by weight of the second hyaluronic acid salt product.

15. Process according to claim 1 , wherein said cross-linking agent is selected from epichlorohydrin, divinyl sulfone, 1,4-bis(2,3-epoxypropoxy)butane, 1,2-bis(2,3-epoxypropoxy)ethylene, 1-(2,3-epoxypropyl)-2,3-epoxycyclohexane, aldehydes, and mixtures thereof.

16. Process according to claim 15 , wherein said aldehydes are selected from formaldehyde, glutaraldehyde, crotonaldehyde, and mixtures thereof.

17. Process according to claim 1 , wherein said cross-linking agent is 1,4-bis(2,3-epoxypropoxy)butane.

18. Process according to claim 9 , wherein the pH is between 7 and 7.4.

19. Process according to claim 9 , wherein the pH is 7.1 and 7.3.

20. A process according to claim 1 , wherein the first hyaluronic acid salt product has a molecular weight of between 10 4 Da and 9.9×10 5 Da, the second hyaluronic acid salt product has a molecular weight of between 1.1×10 6 Da and 5×10 6 Da, said mixture contains more than 50% by weight of the first hyaluronic acid salt product and at least 5% by weight of the second hyaluronic acid salt product.

21. The process according to claim 20 , wherein the second hyaluronic acid salt product has a molecular weight of about 3×10 6 Da.

22. The process according to claim 20 , wherein the first hyaluronic acid salt product has a molecular weight of about 3×10 5 Da.

23. The process according to claim 20 , wherein said mixture contains more than 70% by weight of the first hyaluronic acid salt product.

Assignments (2)
CHANGE OF NAME Recorded May 17, 2010
From: CORNEAL INDUSTRIE
To: ALLERGAN INDUSTRIES SAS
Reel/Frame 024395/0335 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2005
From: LEBRETON, PIERRE
To: CORNEAL INDUSTRIE
Reel/Frame 017576/0409 →
Priority Claims (1)
FR 03 04444 · Apr 10, 2003 · national
Continuity (1)
Related Publication 20060194758A1 · Aug 31, 2006